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extensively studied, but data on survival are still equivocal.
Objective: To assess the effectiveness of surgery combined with preoperative radiotherapy or
postoperative chemoradiotherapy in the reduction of all-cause mortality in patients with
resectable gastric carcinoma.
Methods: Computerised bibliographic searches of MEDLINE and CANCERLIT (1970–2006) were
supplemented with hand searches of reference lists.
Study selection: Studies were included if they were randomised controlled trials (RCTs) com-
paring mortality of surgery combined with preoperative radiotherapy or postoperative chemor-
adiotherapy to surgery alone, and if they included patients with histologically-proven gastric
adenocarcinoma without metastases. Nine eligible RCTs, 4 of preoperative radiotherapy (832
patients) and 5 of postoperative chemoradiotherapy (869 patients), were identified and
included in the meta-analysis.7 Elsevier Ltd. All rights reserved.
RT, chemoradiotherapy; RCTs, randomised controlled trials; CI, confidence interval.
study was sustained by the institutions for which the authors work.
32 236096; fax: +39 0532 237532.
F. Fiorica).
730 F. Fiorica et al.Data extraction: Data on study populations, interventions, and outcomes were extracted from
each RCT according to the intention to treat method by three independent observers and
combined using the DerSimonian and Laird method.
Results: Surgery combined with preoperative radiotherapy compared to surgery alone signifi-
cantly reduced the 3-year (OR 0.57; 95% CI 0.43–0.76: p = 0.0001) and 5-year (OR 0.62; 95%
CI 0.46–0.84; p = 0.002) mortality rate. A significant reduction of the 5-year (OR 0.45; 95%
CI 0.32–0.64; p < 0.00001) mortality rate was observed when surgery followed by chemoradio-
therapy was compared to surgery alone.
Conclusions: In patients with resectable gastric carcinoma, adjuvant radiotherapy significantly
reduces 3-year and 5-year all-cause mortality, but the magnitude of the benefit is relatively
small. Available evidence is inadequate to determine whether postoperative chemoradiother-
apy is superior to preoperative radiotherapy.c 2007 Elsevier Ltd. All rights reserved.Introduction
Worldwide, gastric carcinoma still ranks high in mortality
rate among tumor sites, despite a general decrease in its
incidence.1 The European weighted survival of gastric carci-
noma, calculated from the pool of all carcinoma registries,
was 40% at 1 year and 21% at 5 years.2 The 5-year survival
rate of patients with advanced loco-regional gastric carci-
noma who have undergone curative resection remains low
because of the high risk of local recurrence or distant
metastases even when resection was considered curative.3,4
Thus advanced gastric carcinoma is a treatable, but rarely
curable, disease. The improvement in survival therefore re-
mains a major issue in the long-term management of resect-
able gastric carcinoma.
Improved and standardised surgical techniques, as well as
advances in supportive care, have contributed to an increase
in the rate of curative resection. The current surgical issue
concerns the extent of node resection in clinical practice
(limited versus extended), though a Cochrane meta-analysis5
failed to show a statistically significant benefit for extended
node dissection, and indeed showed an increased postopera-
tive mortality. Nevertheless, a plateau in the effectiveness
of surgical resection may well have been reached, and
further improvement in survival from a single modality ap-
proach seems unlikely.6 Meta-analyses of adjuvant and neo-
adjuvant chemotherapy,7–9 as well as randomised controlled
trials (RCTs) of radiotherapy (RT) as a single adjuvant in the
postsurgical setting10–13 have shown conflicting results.
Since the first RCT of postoperative chemoradiotherapy
(CRT) appeared in 1979,14 several RCTs have been pub-
lished.15–19 The results of these trials are inconclusive or
conflicting because of the relatively small samples. Addi-
tionally, it is difficult to draw general conclusions from them
because of differences in patient characteristics and treat-
ment regimens. A recently published large RCT, the Inter-
group Study INT-0116,19 concluded that postoperative CRT
significantly improves survival compared to surgery alone.
More recently, the preoperative RT approach has become
the focus of interest in an effort to prolong survival and re-
duce recurrence rates in patients with gastric carcinoma.
However, the results of published RCTs20–23 remain incon-
sistent, and the overall assessment of the treatment effect
difficult to assess. The last published RCT, by Skoropad
et al.,23 failed to show a statistically significant benefit onsurvival. Therefore, the role of radiation therapy is far from
definite. The aim of this systematic review and meta-analy-
sis is to determine if there is a benefit of adjuvant radio-
therapy, with or without chemotherapy, compared with
surgery alone.Methods
Selection of randomised trials
This meta-analysis was performed according to the QUOROM
statement.24 Retrieval of RCTs was based on the Cochrane
Controlled Trials Register, The Cochrane Library, MEDLINE,
CANCERLIT and ENBASE, limiting the search to randomised
clinical trials and human studies and using the following
medical subject headings: gastric carcinoma, radiotherapy,
chemotherapy, chemoradiotherapy, randomised or ran-
domised trial25 and clinical trial. The search included liter-
ature published up to December 2006. The computer search
was supplemented with manual searches of reference lists
for all available review articles, primary studies, meetings
abstracts and bibliographies of books, in order to identify
other studies not found in the computer search. When the
results of a single study were reported in more than one
publication, only the most recent and complete data were
included in the meta-analysis.
Studies were included in the meta-analysis if they were
RCTs comparing preoperative RT plus surgery or CRT after
surgery to surgery alone; if they included patients with
resectable or resected histologically-proven gastric carci-
noma without metastatic disease; and if all-cause mortality
was assessed as an outcome measure of the effect of the
treatment. Quasi-randomised trials and observational stud-
ies were excluded. Decisions on which RCTs to include were
taken unblindly by two reviewers (F.F. and C.C.). Disagree-
ments were resolved by discussion. Excluded RCTs were
identified with the reason for exclusion.
Among the reviewed studies, 9 RCTs met the inclusion
criteria.14–16,18–23 Studies were excluded if they did not
have surgery alone as a control group,17 if they were non-
randomised10–12; if they used only intraoperative radiation
therapy (IORT)26; or if they were published as a preliminary
report27,28 and subsequently published as a final paper. As
all the RCTs reported as abstracts were subsequently pub-
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reviewed reports.
In the two Gastrointestinal Tumor Study Group trials15,18
postoperative CRT was compared to surgery followed by
chemotherapy as a control group. To improve the power
of the meta-analysis, we combined the RCTs of postopera-
tive CRT independently of whether postoperative chemo-
therapy was or was not added to surgery as a control
treatment, assuming that they were interventions of unpro-
ven efficacy.7–9 However, sensitivity analysis, pooling the
remaining RCTs after the omission of these two RCTs,15,18
was performed.
Review of the trials
The trials were first reviewed using a list of predefined, per-
tinent issues that concerned the characteristics of patients
and treatments. The methodological quality of the trials
was assessed by two major criteria previously validated29:
adequate treatment allocation concealment and handling
of withdrawals and dropouts. Each quality component was
rated as yes, unclear or no. The quality of trials was
reported according to each separate component. Each RCT
was evaluated and classified by three independent investi-
gators (F.F., C.C., B.C.). Discrepancies among reviewers
were infrequent (overall interobserver variations <10%),
and were resolved by discussion.
Statistical methods
The crude rates of the 3-year and 5-year all-cause mortality
were assessed as measures of the treatment effect. These
data were available in 7 RCTs.16,18–23 In the remaining two
trials,14,15 we used the Kaplan–Meier estimates of the 3-year
and 5-year mortality in the treated and control groups re-
ported in the text. Evaluation of therapeutic effectiveness
was performed by an intention-to-treat method. When not
reported in the trial, the response rate according to inten-
tion-to-treat was calculated. To combine results from indi-
vidual trials, we used the proportion of events observed in
the treated and control groups. With these observed propor-
tions of events, the odds ratio (OR) was computed for each
trial. The overall OR among the frequency of the events in
the postoperative CRT or in the preoperative RT groups
and the surgery-alone group was calculated with models
based on both fixed and random effects assumptions. In
addition to within-study variance, the random effects model
considers heterogeneity among studies. Because of the dif-
ferent clinical settings and groups of subjects analysed,
and because the tests for heterogeneity lack statistical
power due to the few studies included in this meta-analysis,
we have presented the results of random effects models
according to DerSimonian and Laird.30 The 95% confidence
interval (95% CI) of the odds ratio was also calculated. The
overall OR was tested for significance using a Mantel–Haens-
zel v2 test.31 The number needed to treat (NNT) for benefit
and the number needed to harm (NNH) for risk, which both
derive from the inverse of the risk difference, were also used
as a measure of treatment benefit and risk.32 We in turn ex-
cluded each study to ensure that no single study would be
solely responsible for the significance of any result (the
so-called robust analysis). All our analyses were computedusing Metaview 4.0. The number of patients who discontin-
ued their planned protocol because of side effects was also
recorded as a measure of the feasibility of the protocol.
The scales, grades and sites of any acute toxicity information
were extracted from the text. Though all trials reported
acute toxicity of the treatment, several different scales of
measurement were used, and information was frequently al-
ready combined by site or grade. Extracted data were there-
fore grouped as haematological (categorised or grouped) and
gastrointestinal. The total number of toxic events in all trials
was used to calculate a single OR of acute toxicity for each
site and grade grouping (grades I and II combined, grades
III and IV combined).
To improve the comparability of the different therapeutic
regimens, and to assess the relationship between radiation
dose and survival benefit, the biologically effective dose
(BED) corrected for time, and the linear quadratic equivalent
dose (LQED) of the various radiation schedules. were esti-
mated.33 In the trial by Dent,14 patients were randomised
in two divisions: division I with T1-3 N1-2 M0 and division II
with T4 or M1 patients. We included only the first division
with patients withoutmetastases. In the trial by Shchepotin20
two different treatment arms were compared with the same
surgery arm as the control. We included in the analysis only
the preoperative radiotherapy arm of this RCT. Therefore,
the statistical analysis used only independent estimators of
effect size.34 We used subgroup analyses and meta-regres-
sion to explore and explain the diversity (heterogeneity)
among the results of different studies. A v2 for interaction35
was used to examine whether the effect of treatment varied
significantly among different groups of trials.
To examine the extent to which differences in the study
endpoints could be explained by differences in the thera-
peutic regimens, in characteristics of the patients studied,
or in study design features, several independent explana-
tory variables were included in a meta-regression model.36
The dependent variable in the regression analysis was the
logarithmic odds ratio of the 3-year all-cause mortality in
the adjuvant versus surgery-alone group. The statistical
analysis was done by a weighted multiple linear regression
model, where the weights were the inverse of the variance
of the treatment effect. The patient characteristics exam-
ined were mean age, the proportion of patients with posi-
tive nodes in the surgery-alone group, and the proportion
of male patients. The BED was used to characterize each
therapeutic regimen. Study design features that indicate
the quality of RCTs were also examined. These design fea-
tures included the two key domains of allocation conceal-
ment and of handling of withdrawals. For each of these
two key domains, RCTs were divided into high-quality and
low-quality groups and used through a dummy variable. Fi-
nally, study size and study publication year, as a proxy for
technical improvement with time, were also included as
independent variables. Variables with a p-value of <0.10
at univariate analysis were included in the final multivariate
model. For multivariate analysis the number of covariates
was reduced according to the number of retrieved studies
to variable clusters (expressing clinical or technical aspects
of studies) and to clinical judgment. Regression analysis was
performed with the proc REG in SAS.
Publication bias was assessed by the Begg and Mazuma-
dar37 adjusted rank-correlation test for publication bias
732 F. Fiorica et al.and by the Egger et al.38 regression asymmetry test for pub-
lication bias.
Source of support
This meta-analysis was entirely supported by the authors’
respective institutions.
Results
Characteristics of the RCTs
The main features of the trials included in the meta-analysis
are shown in Table 1. The 9 RCTs14–16,18–23 included 1694
patients, 849 of whom received adjuvant radiotherapy,
405 as preoperative treatment20–23 and 444 in postoperative
setting combined with chemotherapy.14–16,18,19 The per-
centage of males ranged from 55%22 to 90%.21 The criteria
for inclusion were uniform in all but one RCT, which in-
cluded only patients with poor prognosis but otherwise
operable tumors.16 Only three studies15,18,19 were multicen-
tre trials. The sample size of each RCT varied greatly, rang-
ing from 2316 to 28119 patients. Mean patient age was
56 years, ranging from 54 to 60. The method of randomisa-
tion was not clearly reported in two studies.14,16 No ade-
quate treatment allocation concealment was used in two
trials15,18 and in two studies15,16 no clearly criteria for han-
dling withdrawals were reported.
The rate of resection (curative or palliative) reported in
all RCTs ranged from 79.4%21 to 100%16,19,22,23. The rate of
D1 versus D2 resection was reported in only one RCT.19
Resection was defined as curative when an agreement
between surgeon and histopathologist that margins of the
resected tissue were free of tumor was reached. The pro-
portion of patients who underwent resection classified
as curative differed greatly among the trials, ranging from
0% to 100%. Data on surgical technique are reported in
Table 1.
Data on the preoperative staging of tumor were lacking
in almost all trials, and stage was assessed in all RCTs at
operation. The rate of patients with positive nodes was
comparable in all RCTs using postoperative CRT, ranging
from 63%14 to 86%.19 Instead, in RCTs using preoperative
RT there was a variability between control and treatment
group ranging from 34.2%22 to 84.9%.21
The therapeutic regimens of the RCTs are shown in Table
2. A large variability of irradiation schedules between trials
was found in the total dose (ranging between 2014,20,22,23
and 45 Gy19); the daily dose (ranging between 1.5616 and
4 Gy20,22,23); the fractions of dose (ranging between
520,22,23 and 3015) given with 2 weeks of rest. All but three
trials used radiation delivered from Co60 source16,19,21 and
only one trial by GTSGII used multiple fields arrangement,
while the others delivered radiation with anterior–posterior
fields.Overall estimates: 3-year and 5-year mortality
The effect of preoperative RT and postoperative CRT on 3-
year overall mortality (9 RCTs: 1700 patients, 1033 deaths)
is shown in Figure 1. Although the effect of treatment onoverall mortality favoured preoperative RT and postopera-
tive CRT in all but three RCTs,14,16,18 a statistically signif-
icant difference was observed in only four.19–22 The OR of
each trial ranged from 0.44 to 1.97. The pooled estimate
of the treatment effect was significant (OR 0.67 (95% CI
0.55–0.82); z = 3.86; p = 0.0001) (NNT = 14). Similar results
were obtained when a fixed effect model was used (OR
0.67 (95% CI 0.55–0.82); z = 3.85; p = 0.0001). In all the ro-
bust analyses, the pooled estimate of the treatment effect
was significant. In particular, robust analyses show that
evaluation of the eight trials remaining after omission of
the largest trial by MacDonald (OR 0.66 (95% CI 0.51–
0.85); z = 3.21; p = 0.001) or the trial by Skoropad22 adding
intraoperative RT (OR 0.69 (95% CI 0.56–0.85); z = 3.47;
p = 0.0005) did not lose statistical significance for 3-year
overall mortality. Finally, sensitivity analysis excluding
the 2 RCTs of postoperative CRT15,18 adding chemotherapy
after surgery in the control group also showed a similar
effect size (OR 0.65 (95% CI 0.53–0.80); z = 4.04;
p < 0.0001).
Five-year mortality due to gastric carcinoma was re-
ported in 7 RCTs (1540 patients: 1042 deaths). The benefit
of preoperative RT and postoperative CRT on 5-year overall
mortality is shown in Figure 2. RT and CRT decreased mor-
tality in all RCTs, and a significant difference was observed
in two trials.19,21 The OR of each trial ranged from 0.15 to
0.88. The pooled estimate of the treatment effect was sig-
nificant (OR 0.54 (95% CI 0.43–0.68), z = 5.37; p < 0.00001)
(NNT = 8). Similar results were obtained when a fixed effect
model was used (OR 0.53 (95% CI 0.43–0.67); z = 5.48;
p < 0.00001). In all the robust analyses, the pooled estimate
of the treatment effect was significant.
Subgroup analyses and meta-regression
We performed subgroup analyses to evaluate whether there
was evidence of differences in the magnitude of the treat-
ment effect among different studies.
The effect of preoperative RT on 3-year overall mortality
(4 RCTs: 832 patients, 488 deaths) favoured all four trials,
reaching statistically significant differences in three.20–22
For 3-year mortality, the pooled OR was statistically signif-
icant in patients who received preoperative RT (OR 0.57,
95% CI 0.43–0.76; z = 3.82; p = 0.0001) but not in those
who received postoperative CRT (5 RCTs: 868 patients,
545 deaths) (OR 0.79, 95% CI 0.59–1.05; z = 1.63;
p = 0.10), with no significant interaction (test for interac-
tion: z = 1.58; p = 0.11).
Five-year overall mortality was significantly lower in pa-
tients who were allocated to preoperative RT (4 RCTs: 832
patients, 556 deaths) than in those allocated to surgery
alone (OR 0.62, 95% CI 0.46–0.84); z = 3.13; p = 0.002
(NNT = 10). Finally, postoperative CRT (3 RCTs: 708 pa-
tients, 486 deaths) also significantly reduces gastric carci-
noma 5-year mortality (OR 0.45, 95% CI 0.32–0.64);
z = 4.58; p < 0.00001 (NNT = 6). We failed to show a signifi-
cant interaction between the pooled OR of preoperative
RT trials and the pooled OR of postoperative CRT trials (test
for interaction: z = 1.37; p = 0.086).
When grouped by LQED10, analysis showed that the
pooled OR for 3-year mortality was 0.65 (95% CI 0.51–
0.83; z = 3.42, p = 0.0006) in RCTs given a dose equivalent
T
a
b
le
1
P
at
ie
n
t
ch
ar
ac
te
ri
st
ic
s
o
f
al
l
tr
ia
ls
in
cl
u
d
e
d
in
th
e
m
e
ta
-a
n
al
ys
is
St
u
d
y
(r
e
fe
re
n
ce
)
Y
e
ar
T
re
at
m
e
n
t
ar
m
Sa
m
p
le
si
ze
(n
)
M
al
e
(%
)
M
e
an
ag
e
P
e
rf
o
rm
an
ce
(%
)
Lo
ca
ti
o
n
o
f
p
ri
m
ar
y
(%
)
St
ag
e
(%
)
T
yp
e
o
f
su
rg
e
ry
(%
)
Su
rg
ic
al
p
ro
ce
d
u
re
s
(%
)
Li
n
fo
a
d
e
n
e
ct
o
m
y
p
ro
ce
d
u
re
s
6
1
>1
C
ar
d
ia
s
C
o
rp
u
s/
an
tr
u
m
N
0
N
+
R
ad
ic
al
N
o
ra
d
ic
al
T
o
ta
l
ga
st
re
ct
o
m
y
P
a
rt
ia
l
ga
st
re
ct
o
m
y
O
th
e
rs
P
o
st
o
p
e
ra
ti
ve
ra
d
io
ch
e
m
o
th
e
ra
p
y
tr
ia
ls
D
e
n
t
e
t
al
.1
4
19
79
S
+
C
R
T
35
n
.r
.
n
.r
.
n
.r
.
n
.r
.
n
.r
.
n
.r
.
37
63
57
.1
28
.6
N
o
t
sp
e
ci
fi
e
d
N
o
t
sp
e
ci
fi
e
d
N
o
t
sp
e
ci
fi
e
d
N
o
t
sp
e
ci
fi
e
d
S
31
n
.r
n
.r
.
n
.r
.
n
.r
.
n
.r
.
n
.r
.
29
71
61
.3
29
.0
G
T
SG
I1
5
19
82
S
+
C
R
T
45
73
n
.r
.
64
36
24
76
n
.r
.
n
.r
.
0
71
.0
N
o
t
sp
e
ci
fi
e
d
N
o
t
sp
e
ci
fi
e
d
N
o
t
sp
e
ci
fi
e
d
N
o
t
sp
e
ci
fi
e
d
S
+
C
T
45
67
n
.r
.
76
24
20
80
n
.r
.
n
.r
.
0
76
.0
M
o
e
rt
e
l
e
t
al
.1
6
19
84
S
+
C
R
T
39
74
58
n
.r
.
n
.r
.
49
51
18
82
n
.r
.
n
.r
.
10
1
7
0
N
o
t
sp
e
ci
fi
e
d
S
23
74
56
n
.r
.
n
.r
.
56
44
22
78
n
.r
.
n
.r
.
90
8
3
0
G
T
SG
II
1
8
19
90
S
+
C
R
T
45
74
n
.r
.
84
16
n
.r
.
n
.r
.
n
.r
.
n
.r
.
0
73
.0
N
o
t
sp
e
ci
fi
e
d
N
o
t
sp
e
ci
fi
e
d
N
o
t
sp
e
ci
fi
e
d
N
o
t
sp
e
ci
fi
e
d
S
+
C
T
50
76
n
.r
.
83
17
n
.r
.
n
.r
.
n
.r
.
n
.r
.
0.
0
70
.0
M
ac
D
o
n
al
d
e
t
al
.1
9
20
01
S
+
C
R
T
28
1
72
60
94
6
21
79
14
86
10
0.
00
0
N
o
t
sp
e
ci
fi
e
d
N
o
t
sp
e
ci
fi
e
d
N
o
t
sp
e
ci
fi
e
d
D
0
re
se
ct
io
n
:
5
4
%
S
27
5
71
59
94
6
18
82
16
84
10
0.
00
0
D
1
re
se
ct
io
n
:
3
6
%
D
2
re
se
ct
io
n
:
1
0
%
P
re
o
p
e
ra
ti
ve
ra
d
io
th
e
ra
p
y
tr
ia
ls
Sh
ch
e
p
o
ti
n
e
t
al
.2
0
19
94
R
T
+
S
98
60
55
n
.r
.
n
.r
.
n
.r
.
n
.r
.
34
66
84
.7
15
.3
50
3
4
.7
1
5
.3
N
o
t
sp
e
ci
fi
e
d
S
10
0
60
55
n
.r
.
n
.r
.
n
.r
.
n
.r
.
37
63
86
.0
14
.0
49
3
7
1
4
Z
h
an
g
e
t
al
.2
1
19
98
R
T
+
S
17
1
90
55
.8
0
n
.r
.
n
.r
.
10
0
0
35
.7
*
64
.3
*
80
.1
9.
4
N
o
t
sp
e
ci
fi
e
d
N
o
t
sp
e
ci
fi
e
d
N
o
t
sp
e
ci
fi
e
d
N
o
t
sp
e
ci
fi
e
d
S
19
9
89
56
.1
0
n
.r
.
n
.r
.
10
0
0
15
.0
1
84
.9
0
61
.8
17
.6
Sk
o
ro
p
ad
e
t
al
.2
2
20
00
R
T
+
S
59
67
54
3
0
70
20
80
57
.5
0
42
.5
0
67
.8
25
.4
32
.2
3
5
.6
3
2
.2
D
1
re
se
ct
io
n
:
1
0
0
%
S
53
55
55
2
6
74
26
74
65
.8
0
34
.2
0
71
.7
28
.3
30
.2
4
1
.5
2
8
.3
Sk
o
ro
p
ad
e
t
al
.2
3
20
02
R
T
+
S
77
68
.6
0
55
n
.r
.
n
.r
.
51
49
49
51
66
.0
31
.0
35
.1
3
2
3
2
.9
D
1
re
se
ct
io
n
:
1
0
0
%
S
75
76
.5
0
54
n
.r
.
n
.r
.
35
65
45
55
68
.0
29
.0
26
.7
4
1
.3
3
2
The impact of radiotherapy on survival in resectable gastric carcinoma: A meta-analysis of literature data 733
T
a
b
le
2
T
h
e
ra
p
e
u
ti
c
re
gi
m
e
n
s
o
f
al
l
tr
ia
ls
in
cl
u
d
e
d
in
th
e
m
e
ta
-a
n
al
ys
is
St
u
d
y
(r
e
fe
re
n
ce
)
R
ad
io
th
e
ra
p
y
C
h
e
m
o
th
e
ra
p
y
Su
rg
e
ry
T
o
ta
l
d
o
se
(G
y)
Fr
ac
ti
o
n
s
(N
o
/d
ay
s)
D
ai
ly
d
o
se
(G
y)
B
E
D
(G
y)
LQ
E
D
1
0
(G
y)
M
ac
h
in
e
Fi
e
ld
s
D
ru
gs
D
o
sa
ge
(m
g/
m
2
)
Sc
h
e
d
u
le
s
(d
a
y)
In
te
rv
a
l
b
e
tw
e
e
n
su
rg
e
ry
a
n
d
b
e
gi
n
n
in
g
o
f
R
T
(w
e
e
ks
)a
In
te
rv
a
l
b
e
tw
e
e
n
e
n
d
o
f
R
T
a
n
d
su
rg
e
ry
(w
e
e
ks
)b
P
o
st
o
p
e
ra
ti
ve
ra
d
io
ch
e
m
o
th
e
ra
p
y
tr
ia
ls
D
e
n
t
e
t
al
.1
4
20
8
2.
5
22
20
.8
C
o
60
A
P
-P
A
m
id
p
la
n
e
5F
U
50
0
m
g
1
–
4
(b
e
fo
re
R
T
),
4
0
–
4
5
,
6
8
–
7
3
,
9
6
–
1
0
1
,
1
2
4
–
1
2
9
,
1
5
2
–
1
5
7
4
–
12
.5
m
g/
kg
G
T
SG
I1
5
50
30
1.
67
39
.2
48
.7
C
o
60
A
P
-P
A
5F
U
50
0
1
–
3
,
3
5
–
3
8
3
–
m
id
p
la
n
e
C
C
N
U
15
0
6
7
–
7
1
5F
U
37
5
6
7
–
7
1
M
o
e
rt
e
l
e
t
al
.1
6
37
.5
24
1.
56
32
.5
36
.1
C
o
60
an
d
Li
n
ac
6
M
V
A
P
-P
A
5F
U
15
m
g/
kg
1
–
3
3
,
5
–
6
–
N
o
sh
ie
ld
in
g
G
T
SG
II
1
8
43
.2
24
1.
8
40
.2
42
.5
C
o
60
M
u
lt
ip
le
fi
e
ld
sh
ie
ld
in
g
ki
d
n
e
y
5F
U
32
5
1
–
5
,
3
6
–
4
0
(1
1
9
)
1
0
–
C
C
N
U
11
0
1
(1
1
9
)
A
D
R
IA
40
1
,
3
6
(1
1
9
)
M
ac
D
o
n
al
d
e
t
al
.1
9
45
25
1.
8
42
.5
44
.2
Li
n
ac
A
P
-P
A
sh
ie
ld
in
g
ki
d
n
e
y
5F
U
42
5
1
–
4
,
2
2
–
2
5
<
5
.8
FA
20
1
–
4
,
2
2
–
2
5
>4
M
V
1
cy
cl
e
b
e
fo
re
R
T
(5
d
a
ys
)
a
n
d
2
cy
cl
e
a
ft
e
r
R
T
P
re
o
p
e
ra
ti
ve
ra
d
io
th
e
ra
p
y
tr
ia
ls
Sh
ch
e
p
o
ti
n
al
.2
0
20
4
5
27
.3
25
C
o
60
A
P
-P
A
–
–
–
–
1
m
id
p
la
n
e
Z
h
an
g
e
t
al
.2
1
40
20
2
40
40
Li
n
ac
8
M
V
A
P
-P
A
m
id
p
la
n
e
–
–
–
–
2
–
4
Sk
o
ro
p
ad
e
t
al
.2
2
20
5
4
27
.3
23
.3
C
o
60
A
P
-P
A
m
id
p
la
n
e
–
–
–
–
1
20
c
1
c
20
c
64
.4
c
50
c
Sk
o
ro
p
ad
e
t
al
.2
3
20
5
4
27
.3
0
23
.3
C
o
60
A
P
-P
A
m
id
p
la
n
e
–
–
–
–
1
B
E
D
:
b
io
lo
gi
ca
l
e
q
u
iv
al
e
n
t
d
o
se
;
LQ
E
D
1
0
:
li
n
e
ar
q
u
ad
ra
ti
c
e
q
u
iv
al
e
n
t
d
o
se
;
A
P
-P
A
:
an
te
ro
p
o
st
e
ri
o
r
fi
e
ld
s;
M
id
p
la
n
e
:
n
o
rm
al
iz
at
io
n
o
f
tr
e
at
m
e
n
t
at
m
id
p
la
n
e
;
5-
FU
,
5-
fl
u
o
ro
u
ra
ci
l;
C
C
N
U
,
lo
m
u
st
in
e
;
A
D
R
IA
,
D
o
xo
ru
b
ic
in
;
F
A
,
le
u
co
vo
ri
n
.
Fo
r
e
xp
an
si
o
n
o
f
th
e
st
u
d
y
n
am
e
s,
se
e
co
rr
e
sp
o
n
d
in
g
re
fe
re
n
ce
.
a
P
o
st
o
p
e
ra
ti
ve
ch
e
m
o
ra
d
io
th
e
ra
p
y.
b
P
re
o
p
e
ra
ti
ve
ra
d
io
th
e
ra
p
y.
c
In
tr
ao
p
e
ra
ti
ve
ra
d
io
th
e
ra
p
y.
734 F. Fiorica et al.
Figure 1 3-year overall mortality. Meta-analysis of 9 RCTs of postoperative chemoradiotherapy (5 RCTs) and preoperative
radiotherapy (4 RCTs) for respectable gastric carcinoma using a random effects model. The odds ratio (OR) and 95% confidence
interval (CI) for the effect of treatment on 3-year all-cause mortality are shown on a logarithmic scale. Studies are arranged by
publication year. Study names are provided in the corresponding references.
Figure 2 5-year overall mortality. Meta-analysis of 9 RCTs of postoperative chemoradiotherapy (5 RCTs) and preoperative
radiotherapy (4 RCTs) for respectable gastric carcinoma using a random effects model. The odds ratio (OR) and 95% confidence
interval (CI) for the effect of treatment on 3-year all-cause mortality are shown on a logarithmic scale. Studies are arranged by
publication year. Study names are provided in the corresponding references.
The impact of radiotherapy on survival in resectable gastric carcinoma: A meta-analysis of literature data 735to 2 Gy/die of 40 Gy or greater and 0.71 (95% CI 0.49–1.03;
z = 1.82, p = 0.07) in those given a LQED10 less than 40 Gy,
without a significant interaction.
When grouped by radiation machine, analysis showed
that the pooled OR for 3- and 5-year mortality were, respec-tively, 0.68 (95% CI 0.49–0.94; z = 2.31, p = 0.02) and 0.62
(95% CI 0.43–0.90; Z = 2.52, p = 0.01) in RCTs given RT with
cobalt source and 0.66 (95% CI 0.51–0.86; z = 3.09,
p = 0.002) and 0.50 (95% CI 0.38–0.66; z = 4.84, p <
0.00001) in LINAC treated patients.
736 F. Fiorica et al.Because a qualitative heterogeneity in the direction of
the treatment benefit was found for the 3-year mortality
in the postoperative setting, we performed univariate
meta-regression. Neither patient characteristics (mean
age, proportion of male patients, location of the primary
site, and proportions of patients with positive nodes in the
surgery-alone group) nor the different therapeutic regimens
(RT versus CRT, BED) had an effect on the response to treat-
ment (Table 3). Moreover, the two key domains of alloca-
tion concealment and of handling of withdrawals failed to
influence the reported odds ratio of the 3-year mortality.
At univariate analysis the explanatory variables that influ-
enced the reported treatment effect were the study sample
size (p = 0.024), the study publication year (p = 0.0006) and
the proportion of curative resection (p = 0.023) (Table 3).
The multivariate analysis (Table 3), which simultaneously
took into account all these three explanatory variables,
showed that the 3-year mortality was significantly affected
by study sample size only.Figure 3 Postoperative mortality. Meta-analysis of 4 RCTs of pre
random effects model. The odds ratio (OR) and 95% confidence inte
(90 days in-hospital mortality) are shown on a logarithmic scale. Stu
in the corresponding references.
Table 3 Meta-regression analysis for the treatment effect on 3-
Covariates Univariate
Coefficien
Mean age 0.77
Percentage of males -0.10
Percentage of location of primary (corpus/antrum) 0.04
Percentage of positive nodes 0.084
RT versus CRT 4.37
BED (Gy) 0.22
Percentage of curative resection 0.10
Study publication year 0.42
Study sample size 0.027
Allocation concealment* 5.80
Handling of withdrawals* 4.93
Note: The dependent variable is the observed log-odds ratio for morta
estimated variance of the log-odds ratios. SE, standard error of th
biologically effective dose.
* For each of these two components of the quality score, RCTs were d
dummy variable.Compliance, acute and late adverse effects
Compliance with preoperative RT was generally satisfactory.
Analysing RCTs using preoperative RT all irradiated patients
completed neo-adjuvant treatment and no patients required
a reduction of the irradiation dose. The risk of postoperative
mortality (within 90 days) in the RCTs of preoperative RT was
lower in all20–22 but one23 RCT (Fig. 3). A combination of the
data from the four RCTs, which included 745 patients,
showed no significant effect of RT on reduction of postoper-
ative mortality (OR 0.61 (95% CI 0.24–1.57); z = 1.02,
p = 0.31). Preoperative RT did not increase anastomotic
leakage (the most frequent complication of surgery) OR
0.60; 95% CI 0.26–1.38; z = 1.21, p = 0.22.
Compliance with postoperative CRT was unsatisfactory,
and 232 out of 832 (26.7%) patients did not complete the
planned protocol. Severe and life-threatening toxicities
(grades III and IV) are shown in Table 4. Haematological tox-
icity was most frequently recorded, and was reported to beoperative radiotherapy for resectable gastric carcinoma using a
rval (CI) for the effect of treatment on postoperative mortality
dies are arranged by publication year. Study names are provided
year overall mortality
analysis Multivariate analysis
t SE p-Value Coefficient SE p-Value
1.32 0.59 – – –
0.21 0.66 – – –
0.08 0.60 – – –
0.11 0.49 – – –
3.22 0.21 – – –
0.24 0.38 – – –
0.035 0.022 0.038 0.029 0.26
0.14 0.024 0.10 0.12 0.42
0.004 0.0006 0.02 0.006 0.034
3.73 0.16 – – –
3.90 0.24 – – –
lity from each trial. Weights have been assigned according to the
e coefficient. RT, radiotherapy; CRT, chemoradiotherapy; BED,
ivided into high-quality and low-quality groups and used through a
Table 4 Acute toxicity grades III and IV of the 5 RCTs of postoperative CRT
Toxicity Number of RCTs Trt events/patients Ctrl events/patients OR (95% CI) p-Value
Haematological 514–16,18,19 209/432 25/420 16.70 (10.69–26.09) <0.00001
Gastrointestinal 514–16,18,19 156/432 13/420 17.70 (9.85–31.80) <0.00001
Mucosites 314,18,19 33/352 1/352 36.31 (4.94–267.02) 0.0004
Toxic effects global 314,16,18,19 111/352 24/344 4.61 (2.89–7.36) <0.00001
Death 514–16,18,19 6/432 1/420 5.90 (0.71–49.23) 0.10
Trt events: number of patients with side effects in treatment group.
Ctrl events: number of patients with side effects in control group.
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tients in the CRT group compared to the control group (hae-
matological: 48.4% versus 6%, p < 0.00001) (NNH = 2). Grade
III or IV gastrointestinal toxicity was also greater in the adju-
vant group than in the control group (36.1% versus 3%
p < 0.00001) (NNH = 3). In none of the RCTs was late toxicity
systematically recorded. Seven toxic deaths were reported
in the published papers, one in the control group and 6 in
the adjuvant group (p = 0.10).Figure 5 3-years funnel plot. A skewness in this graph
indicates publication bias.
Figure 4 Egger’s publication bias plot. The standardised log-
odds ratio for 3-year mortality is plotted against the precision
of the log-odds ratio along with the regression line about the
intercept. A p-value <0.1 (suggesting asymmetry in the funnel
plot) might give evidence of publication bias.Publication bias
The Egger’s publication bias plot and the funnel plot for the
3-year mortality are shown in Figures 4 and 5. Egger and
Begg tests for publication bias showed that the risk of having
missed or overlooked trials, though not significant, was sub-
stantial: the p-values were 0.13 by the Egger’s test and 0.06
by the Begg’s test for 3-year mortality. For 5-year mortality,
the p-values were 0.20 by the Egger’s test and 0.10 by the
Begg’s test.
Discussion
Outcomes in patients with gastric carcinoma undergoing
surgery remain disappointing,39 even when resection was
considered curative. The high local and distant failure rates
suggest a need for both local and systemic adjuvant treat-
ment. In this meta-analysis of literature data on 1700 pa-
tients in 9 RCTs of adjuvant radiotherapy for resectable
gastric carcinoma, we found that radiotherapy both before
and after surgery, with or without chemotherapy, signifi-
cantly reduces 3-year and 5-year overall mortality versus
surgery alone. The magnitude of the overall effect was
small but clinically relevant.
The key clinical question is whether preoperative RT is
superior to postoperative CRT in treating patients with
resectable gastric carcinoma. The benefit on 5-year all-
cause mortality was greater in patients who received
postoperative CRT (NNT = 6) than in those who received pre-
operative RT (NNT = 10). However, this difference was not
significant, and there was evidence that CRT increased se-
vere or life-threatening toxicities and risk of death from
causes unrelated to gastric carcinoma. Furthermore, post-
operative CRT is not easy to perform, and 52% of patients
did not complete the planned protocol. Finally, an advan-
tage of adjuvant postoperative CRT is that it can be recom-
mended after incomplete surgical resection in patients with
locally advanced disease.
By contrast, preoperative treatment was better toler-
ated than postoperative treatment, and patients were more
likely to receive all the planned doses of radiation. Short-
term preoperative RT is delivered over 5 days, thus not
delaying surgery. It has been reported that cancer cells
damaged after radiotherapy need time to undergo necrosis,
and that non-viable cancer cells may look morphologically
intact shortly after irradiation.40 We believe, however, that
the available information is inadequate to determine
whether a short course of high-dose radiation (20 Gy over
5 days) is better than a conventional long course regimen.
738 F. Fiorica et al.There is no evidence that preoperative RT significantly in-
creases postoperative mortality or anastomotic leakage.
Further, delivering RT preoperatively could enhance the
rate of curative surgery and offer the theoretical advantage
of treating a tumor with intact vascularisation, without fi-
brotic remodeling of the tumor bed following surgical tumor
removal. Finally, a disadvantage of preoperative RT is that
no pathological data are available to help guide its use.
What are the implications of these results for current
practice? At the moment, National Comprehensive Cancer
Network guidelines (NCCN) recommend adjuvant chemora-
diation following complete surgical resection in locally
advanced or node positive gastric carcinoma patients or in
patients with microscopically positive margins.41 Because
the increased risk of treatment-related death in the chemo-
radiation postoperative setting has been largely counterbal-
anced by the reduction in the all-cause mortality, there was
a clear benefit of CRT with respect to long-term 5-year mor-
tality. Fewer patients need to be treated by CRT to benefit
from the treatment long term than need to be treated to be
harmed postsurgery. So, according to current guidelines we
believe that the benefits of postoperative CRT may out-
weigh the risks for patients at high local and distant recur-
rence rates, whereas the risks outweigh the benefits for
patients with low probability of local and distant failure.
On the other hand, preoperative RT could be recommended
for low-risk patients. However, firm conclusions on the re-
sults of direct comparisons between preoperative RT and
postoperative CRT are hampered by the fact that, to date,
no trial has been performed to compare these adjuvant
treatments. Although this meta-analysis is the most reliable
available assessment of the net effects of preoperative RT
and postoperative CRT on overall mortality, it would be un-
safe to conclude that postoperative CRT is superior to pre-
operative RT in treating patients with resectable gastric
carcinoma. Further large RCTs, stratifying patients accord-
ing to pre-treatment staging by endoscopic ultrasonogra-
phy42 and CT scan,43 are needed to obtain a reliable
direct comparison between radiotherapy before and after
surgery.
Though a great deal of effort was made to identify the
optimal chemoradiotherapy regimen that would increase
the cost effectiveness of therapy in the trials considered
in our study, there was considerable variation in the irradi-
ation procedures, suggesting that broadly accepted and
standardised radiation techniques are needed to obtain
comparable data on the efficacy and safety profiles, partic-
ularly regarding the total and daily dose of radiation and
the type and dose of drug administered. Recently, the re-
sults of the new RTOG 9904 phase II trial in patients with
localized gastric adenocarcinoma44 suggest that preopera-
tive CRT followed by surgery after 5–6 weeks caused a sub-
stantial pathological response and a longer survival.
Surgery, radiotherapy alone or in combination with chemo-
therapy all play roles in the treatment of gastric carcinoma.
The difficulty, however, is that we do not know the opti-
mum permutation.
The results of this retrospective analysis are subject to
several limitations. Overall, the number of patients in-
cluded in the available studies was relatively small, suggest-
ing that interpretation of the cumulative estimates should
be cautious. The confidence intervals around the estimatesof effect are wide in the CRT postsurgical setting because
the trials are heterogeneous and the sample sizes, even with
pooled analyses, are small. As in all meta-analyses, the
methodology of the current study results in a potential lim-
itation of the generalizability of its results to new popula-
tions and settings, as these were obtained in small RCTs
performed in highly specialized centres, while many pa-
tients with gastric carcinoma are cared for outside such
centres.
Differences in the baseline severity of illness in the pop-
ulation of the RCTs, in the irradiation techniques, and in the
CRT regimens may limit the accuracy of this meta-analysis.
The benefit of adjuvant radiotherapy on 3-year mortality
was difficult to assess, particularly across the five studies
of postoperative CRT with one trial showing a significant de-
crease of death risk, three trials showing the opposite, and
one trial showing nearly equivalent survival with the two
treatments. An attempt to control for these differences
was made by including covariates that described the pa-
tients studied and the study design features. However, we
did not find patient characteristics or difference in the ther-
apeutic regimens significantly correlated with the response
to treatment. On the other hand, we found that the study
publication year was significant associated with treatment
benefit. The trend toward an association of year of publica-
tion with the log-OR for 3-year mortality at univariate anal-
ysis was likely related to the increasing skill with which the
diagnostic and therapeutic procedures were performed over
time.
Meta-regression analysis identified study sample size as
the only variable independently associated with a reduc-
tion of the 3-year mortality. This association is due to
the landmark trial by Macdonald et al. in the postoperative
CRT setting, which is the largest study performed so far
and showed the highest treatment benefit. The association
of sample size with the log-OR for 3-year mortality at mul-
tivariate analysis showed that this association was indepen-
dent, and that it most likely depended on the inclusion of
patients who underwent a radical surgical resection in the
trial by Macdonald et al. Resection of all detectable dis-
ease was strictly required for participation in this trial.
These summary results describe only those between study,
not patient, variation because they reflect group averages
rather than individual data. Lack of data on quality-assur-
ance measures of surgical technique could also affect the
accuracy of the results. According to recent reports, the
proportion between metastatic and examined lymph nodes
(N-ratio) has been proposed as an independent prognostic
factor of survival in patients with gastric cancer.45,46 Mar-
chet et al. have demonstrated, in a large cohort of patients
who underwent radical resection for gastric carcinoma,46
that age, T-category, type of resection and N-ratio were
independent predictors of survival. So, data on quality
and type of current surgical procedures are needed to ob-
tain comparable data on efficacy and safety, particularly
regarding the type of resection, the extension of lymph
node surgical dissection and the N-ratio.46 Finally, we
should be particularly concerned about publication bias in
settings in which small studies are being conducted. The
risk of having missed or overlooked trials in this setting
was substantial, as assessed by tests for publication bias
and funnel plot.
The impact of radiotherapy on survival in resectable gastric carcinoma: A meta-analysis of literature data 739In patients with resectable gastric carcinoma, the
available evidence from the literature data is sufficient to
conclude the following: (1) radiotherapy as a single or
combined with chemotherapy adjuvant significantly reduces
3-year and 5-year mortality compared with surgery alone;
(2) the largest reduction in 5-year overall mortality was in
studies of postoperative CRT; (3) treatment-related mortal-
ity in the postoperative follow-up was not significantly in-
creased by CRT, despite the higher rate of side effects;
and (4) preoperative RT is safe and definitely reduces 3-year
and 5-year mortality.
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